In vitro effects of thirty-eight cardiac drugs on human serum paraoxonase

dc.authorid0000-0001-7745-7736en_US
dc.authorid0000-0001-7092-8857en_US
dc.contributor.authorArgan, Onur
dc.contributor.authorÇıkrıkcı, Kübra
dc.contributor.authorUslu, Harun
dc.contributor.authorGencer, Nahit
dc.date.accessioned2023-09-27T11:11:36Z
dc.date.available2023-09-27T11:11:36Z
dc.date.issued2022en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.departmentFakülteler, Fen-Edebiyat Fakültesi, Kimya Bölümüen_US
dc.descriptionArgan, Onur (Balikesir Author)en_US
dc.description.abstractIn this study, the effects of 38 commonly used cardiac drugs on the human paraoxonase (PON1) were investigated. PON1 was purified from human serum blood by ammonium sulfate precipitation (60%-80%) and hydrophobic interaction chromatography (Sepharose-4B similar to L-tyrosine-1-napthylamine gel). All of the cardiac drugs inhibited PON1 at the micro molar level. IC50 and K-i values were determined for each drug. The tested drugs displayed potent PON1 inhibitory activity. It was found that the weakest PON1 inhibitors are Irbesartan (K-i: 421.73 mu M), Glyceryl Trinitrate (K-i: 351.48 RM), and Apixaban (K-i: 333.27 mu M). Bisoprolol hemifumarate (k(i): 269.31 mu M) is also other weak PON1 inhibitor. Therefore, these drugs, having weak PON1 inhibitory activity, may be preferred primarily in patients with atheroclerotic heart disease compared to other drugs due to the protective effect of PON1 on atherosclerosis. Conversely, the most potent inhibitors against PON1 were propafenone (K-i: 0.35 mu M), lacidipine (K-i: 0.78 mu M), I,idocaine HCl (K-i: 1.78 mu M), and Propranolol (K-i : 1.86 mu M). Molecular docking was also applied to confirm the activity of some cardiac drugs on PON1.en_US
dc.identifier.doi10.1111/cbdd.14054
dc.identifier.endpage89en_US
dc.identifier.issn1747-0277
dc.identifier.issn1747-0285
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85128177777
dc.identifier.scopusqualityQ2
dc.identifier.startpage80en_US
dc.identifier.urihttps://doi.org/10.1111/cbdd.14054
dc.identifier.urihttps://hdl.handle.net/20.500.12462/13440
dc.identifier.volume100en_US
dc.identifier.wosWOS:000780872800001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofChemical Biology & Drug Designen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectCardiac Drugsen_US
dc.subjectEnzyme İnhibitionen_US
dc.subjectMolecular Dockingen_US
dc.subjectParaoxonaseen_US
dc.titleIn vitro effects of thirty-eight cardiac drugs on human serum paraoxonaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
onur-argan.pdf
Boyut:
1.13 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: